QUOTED. 15 November 2019. Krishna Rocha-Singh.
Ongoing scrutiny has not explained an apparent link between paclitaxel-coated cardiac devices and an increased mortality rate, speakers said at the Vascular Interventional Advances (VIVA) 2019 conference in Las Vegas. See what Krishna Rocha-Singh, a VIVA board member, said about it here.
“The most comprehensive analysis to date demonstrates a modest yet consistent mortality signal in patients exposed to paclitaxel. However, it did not identify an explanation and I would suggest to you today that it is time to turn the page.” – Krishna Rocha-Singh, board member, VIVA
Click here for a free trial of Medtech Insight